



**FOR IMMEDIATE RELEASE**

**Alnara Pharmaceuticals to Present at 28<sup>th</sup> Annual J.P. Morgan Healthcare Conference**

**Cambridge, Mass., January 6, 2010** – Alnara Pharmaceuticals, a pharmaceutical company developing novel, non-systemic orally delivered protein therapeutics for the treatment of metabolic diseases, today announced that Alexey Margolin, Ph.D., president and chief executive officer of Alnara, is scheduled to present an overview of the company at the 28th Annual J.P. Morgan Healthcare Conference on Monday, January 11, 2010 at 11:00 a.m. PST in Room F. The conference is being held January 11-14 at the Westin St. Francis Hotel in San Francisco, California.

**About Alnara**

Alnara Pharmaceuticals, Inc. is dedicated to developing and commercializing novel protein therapeutics for the treatment of metabolic diseases. The company's innovative approach focuses on designing effective protein therapies that can be orally delivered directly to the gastrointestinal tract without being absorbed into the bloodstream. Alnara's lead product is liprotamase, a novel, non-porcine pancreatic enzyme replacement therapy, which has completed Phase 3 clinical development in collaboration with the Cystic Fibrosis Foundation Therapeutics, Inc. (CFFT). The company is committed to bringing breakthrough new treatments to patients with unmet medical needs. Based in Cambridge, Massachusetts, Alnara is backed by an experienced management team and top-tier venture investors, including Frazier Healthcare Ventures, Third Rock Ventures and Bessemer Venture Partners. For more information, please visit the company's website at [www.alnara.com](http://www.alnara.com).

**Contacts:**

Michele Rozen  
Pure Communications, Inc.  
617-730-8284

Robert Gallotto  
Chief Business Officer  
Alnara Pharmaceuticals  
617-349-3690

###